Deborah L. White

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · New England Journal of Medicine · 2014 · 1.4K citations · Full text

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

Charles G. Mullighan, Christopher B. Miller, Ina Radtke et al. · Nature · 2008 · 1.1K citations

Hematological Malignancy, Bcr–abl1 Lymphoblastic Leukaemia, Hematology +4

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 696 citations

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

Deborah L. White, Verity A Saunders, Phuong Dang et al. · Blood · 2006 · 430 citations · Full text

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Deborah L. White, Verity A Saunders, Phuong Dang et al. · Blood · 2007 · 330 citations